Mer­ck­'s neu­ro-in­spired buy­out; Bay­er's bad week; One launch, one shut­down for Flag­ship; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

De­spite the short week, there were some pret­ty in­ter­est­ing sto­ries. No mat­ter where you are read­ing from, hap­py (Thanks­giv­ing) week­end!

Mer­ck’s neu­ro-in­spired buy­out

In a push to broad­en its neu­ro­science pipeline, Mer­ck is snap­ping up a pri­vate biotech fo­cused on ge­net­i­cal­ly de­fined neu­rode­gen­er­a­tive dis­or­ders and rare dis­eases. Car­away Ther­a­peu­tics share­hold­ers can earn up to $610 mil­lion from the buy­out, in­clud­ing an undis­closed up­front. The biotech is de­vel­op­ing a slate of pre­clin­i­cal small mol­e­cules de­signed to clear tox­ic pro­teins from cells, and a Mer­ck ex­ec­u­tive tells us “they’ve reached an in­flec­tion point that it makes sense for Mer­ck to take over.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER